Stock NVCR NOVOCURE LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
12.64 USD +3.31% Intraday chart for NovoCure Limited +4.51% -15.37%
Apr. 24 NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer CI
Apr. 10 Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 8,340 17,615 7,795 7,698 1,595 1,360 - -
Enterprise Value (EV) 1 8,312 17,810 8,148 8,148 1,923 1,428 1,594 1,533
P/E ratio -1,204 x 865 x -134 x -83.4 x -7.66 x -7.19 x -6.89 x -7.19 x
Yield - - - - - - - -
Capitalization / Revenue 23.7 x 35.6 x 14.6 x 14.3 x 3.13 x 2.53 x 2.34 x 2.07 x
EV / Revenue 23.7 x 36 x 15.2 x 15.1 x 3.78 x 2.65 x 2.74 x 2.34 x
EV / EBITDA 1,102 x 450 x -239 x -103 x -8.67 x -6.41 x -7.05 x -6.48 x
EV / FCF 515 x 212 x 139 x 864 x -19.2 x -10.5 x -12.7 x -9.29 x
FCF Yield 0.19% 0.47% 0.72% 0.12% -5.22% -9.55% -7.87% -10.8%
Price to Book 38.5 x 37.2 x 19 x - - - - -
Nbr of stocks (in thousands) 98,969 101,797 103,819 104,950 106,861 107,606 - -
Reference price 2 84.27 173.0 75.08 73.35 14.93 12.64 12.64 12.64
Announcement Date 2/27/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 351.3 494.4 535 537.8 509.3 538.3 580.7 656
EBITDA 1 7.546 39.55 -34.08 -78.9 -221.9 -222.8 -226.1 -236.7
EBIT 1 -0.914 30.4 -44.33 -89.52 -232.9 -225.4 -236.6 -223.1
Operating Margin -0.26% 6.15% -8.29% -16.64% -45.72% -41.87% -40.74% -34.01%
Earnings before Tax (EBT) 1 -8.824 18.1 -52.08 -81.85 -191.7 -177.8 -201.5 -191.8
Net income 1 -7.23 19.81 -58.35 -92.53 -207 -188.9 -203.4 -198.3
Net margin -2.06% 4.01% -10.91% -17.2% -40.65% -35.1% -35.02% -30.22%
EPS 2 -0.0700 0.2000 -0.5600 -0.8800 -1.950 -1.758 -1.833 -1.758
Free Cash Flow 1 16.14 84.18 58.59 9.43 -100.4 -136.4 -125.5 -165
FCF margin 4.59% 17.03% 10.95% 1.75% -19.72% -25.33% -21.61% -25.15%
FCF Conversion (EBITDA) 213.82% 212.84% - - - - - -
FCF Conversion (Net income) - 424.98% - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/27/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 133.6 133.2 137.5 140.9 131 128.4 122.2 126.1 127.3 133.8 131.4 133.8 135.9 137.5 140
EBITDA 1 -5.818 -20.73 1.804 -18.47 -21.95 -40.28 -57.53 -59.94 -55.44 -48.99 -58.96 -58.36 -56.34 -49.1 -59.85
EBIT 1 -8.552 -23.4 -0.806 -21.13 -24.61 -42.98 -60.25 -62.66 -58.24 -51.72 -53.81 -55.56 -57.3 -58.74 -62.83
Operating Margin -6.4% -17.56% -0.59% -15% -18.79% -33.46% -49.31% -49.71% -45.75% -38.66% -40.93% -41.54% -42.18% -42.71% -44.89%
Earnings before Tax (EBT) 1 -10.53 -25.57 -2.515 -23.36 -23.42 -32.56 -51.08 -53.9 -48.22 -38.53 -41.45 -43.5 -45.57 -47.29 -54.14
Net income 1 -13.12 -26.46 -4.647 -24.01 -26.58 -37.3 -53.06 -57.42 -49.48 -47.08 -45.15 -46.45 -48.04 -49.17 -54.14
Net margin -9.82% -19.86% -3.38% -17.04% -20.29% -29.05% -43.43% -45.55% -38.87% -35.19% -34.35% -34.73% -35.36% -35.75% -38.68%
EPS 2 -0.1300 -0.2500 -0.0400 -0.2300 -0.2500 -0.3600 -0.5000 -0.5400 -0.4600 -0.4500 -0.4198 -0.4335 -0.4460 -0.4548 -0.4350
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 10/28/21 2/24/22 4/28/22 7/28/22 10/27/22 2/23/23 5/4/23 7/27/23 10/26/23 2/22/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 195 353 450 328 67.9 234 173
Net Cash position 1 27.9 - - - - - - -
Leverage (Debt/EBITDA) - 4.936 x -10.37 x -5.706 x -1.478 x -0.3049 x -1.036 x -0.7318 x
Free Cash Flow 1 16.1 84.2 58.6 9.43 -100 -136 -125 -165
ROE (net income / shareholders' equity) -4.38% 5.71% -13.2% -21.7% -51.5% -68.4% -153% -420%
ROA (Net income/ Total Assets) -1.77% 2.59% -5.33% -7.94% -17.7% -19% -25.5% -19.3%
Assets 1 409.6 765.7 1,096 1,166 1,169 992.2 797.2 1,026
Book Value Per Share 2.190 4.660 3.950 - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 10.5 15 24.2 21.4 27.1 24.5 26.5 36
Capex / Sales 2.98% 3.03% 4.52% 3.97% 5.32% 4.55% 4.56% 5.49%
Announcement Date 2/27/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for NovoCure Limited

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
12.64 USD
Average target price
26.17 USD
Spread / Average Target
+107.10%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

1st Jan change Capi.
NOVOCURE LIMITED Stock NovoCure Limited
-15.37% 1.36B
SHOCKWAVE MEDICAL, INC. Stock Shockwave Medical, Inc.
+73.17% 12.38B
PENUMBRA, INC. Stock Penumbra, Inc.
-18.74% 7.92B
MASIMO CORPORATION Stock Masimo Corporation
+16.15% 7.2B
GETINGE AB Stock Getinge AB
+4.81% 5.84B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD. Stock Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
+5.99% 5.01B
APT MEDICAL INC. Stock APT Medical Inc.
+27.07% 4.53B
ASAHI INTECC CO., LTD. Stock Asahi Intecc Co., Ltd.
-21.67% 3.88B
INARI MEDICAL, INC. Stock Inari Medical, Inc.
-40.82% 2.23B
SKAN GROUP AG Stock SKAN Group AG
+1.49% 2.02B
Medical Equipment
  1. Stock Market
  2. Equities
  3. NVCR Stock
  4. Financials NovoCure Limited